For adults (18+ years) with
relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (ALL)


For adult patients
with relapsed or refractory
mantle cell lymphoma (MCL)

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia in ZUMA-3. Abstract 7010. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 2-6, 2022; Chicago, IL. 3. KYMRIAH® (tisagenlecleucel). Prescribing information. Novartis Pharmaceuticals Corporation; 2022. 4. U.S. FDA approves Kite’s TECARTUS®, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company; July 24, 2020. Accessed July 26, 2022.